Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
Withdrawn before enrolling
Conditions studied: Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
In brief
Major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes1. However, the optimal A1c target after transplantation has not been studied. The objective is to understand the optimal A1c target post liver and combined liver and kidney transplant. Strict A1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant.
Key facts
- Study ID
- NCT04216303
- Run by
- Methodist Health System
- People needed
- 0
- Starts
- 2019-09-12
- Expected to finish
- 2021-08-19
- Last updated by the study team
- 2021-09-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All patients 18 years old or older in the United States with diabetes undergoing or post liver and combined liver and kidney transplant from January 2008 to December 2018.
You may not qualify if…
- <18 years old
Where it is running
- Methodist Health System — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.